FDA has about one month of user fee funds left, Got­tlieb warns

As the House preps to take ac­tion on in­di­vid­ual ap­pro­pri­a­tions bills this week, in­clud­ing one that will fund the FDA, Com­mis­sion­er Scott Got­tlieb has fur­ther clar­i­fied what the agency has left in user fee funds, what re­view ac­tiv­i­ties will take place and how the agency is help­ing its em­ploy­ees con­duct in­spec­tions.

Due to the par­tial shut­down, the FDA can­not ac­cept new 2019 user fees, which means the agency can­not ac­cept new med­ical prod­uct ap­pli­ca­tions un­less they are user-fee-pro­gram re­lat­ed but don’t re­quire the pay­ment of a user fee, which is “a very small sub­set of ap­pli­ca­tions,” Got­tlieb not­ed.

And though the FDA will con­tin­ue to work on ex­ist­ing ap­pli­ca­tions where user fees were paid pri­or to 22 De­cem­ber 2018, FDA can on­ly use user fee car­ry­over bal­ances from FY 2018, and Got­tlieb not­ed that among the med­ical prod­uct user fee pro­grams, the one that will run out of car­ry­over bal­ance first is like­ly the Pre­scrip­tion Drug User Fee Act (PDU­FA) funds, which are used for new drug re­views. “We have about one month of fund­ing left,” Got­tlieb said.

Got­tlieb has promised to re­lease fur­ther in­for­ma­tion on the ac­count bal­ances, burn rate and ap­prox­i­mate­ly how long ac­tiv­i­ties can con­tin­ue un­der car­ry­over bal­ances, ac­cord­ing to the non­prof­it Al­liance for a Stronger FDA’s shut­down toolk­it.

On the gener­ic drug end, dur­ing the par­tial shut­down, the FDA will not ac­cept gener­ic drug sub­mis­sions that re­quire pay­ment of a fee.

Got­tlieb clar­i­fied that FDA will be able to process cer­tain sub­mis­sions for gener­ic drugs us­ing car­ry­over user fees, such as changes be­ing ef­fect­ed (CBE) and pri­or ap­proval sup­ple­ments, amend­ments, an­nu­al re­ports and ap­pli­ca­tions for positron emis­sion to­mog­ra­phy (PET) drugs. He al­so said that the agency can ac­cept drug mas­ter files (DMFs) to be ref­er­enced in gener­ic drug ap­pli­ca­tions, but that the agency won’t be able to con­duct ini­tial com­plete­ness as­sess­ments on Type II ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) DMFs if the user fee has not been paid.

“Spon­sors who haven’t paid GDU­FA fa­cil­i­ty fees for FY19 shouldn’t re­mit pay­ment dur­ing the lapse pe­ri­od be­cause FDA can­not ac­cept the fees,” he added.

And if a gener­ic drug ap­pli­ca­tion ref­er­ences, for the first time af­ter 22 De­cem­ber 2018, a Type II API DMF for which the fee has not been paid, then FDA will no­ti­fy the ap­pli­cant that the fee must be paid with­in 20 cal­en­dar days. If the fee is not paid with­in 20 cal­en­dar days of that no­tice, the FDA will not re­ceive the ap­pli­ca­tion. “At this time, FDA has not de­ter­mined what ap­proach it will take if the 20-cal­en­dar-day pe­ri­od ex­pires dur­ing the lapse pe­ri­od,” Got­tlieb said.


While prais­ing the work of FDA staff con­duct­ing crit­i­cal in­spec­tions of food and drug fa­cil­i­ties who are in an “un­paid, ex­cept­ed sta­tus,” mean­ing they’re work­ing on crit­i­cal pub­lic health func­tions with­out pay or re­im­burse­ment, Got­tlieb said the em­ploy­ees’ work has not gone un­no­ticed.

“We’ll sup­port them in any way we can in their ex­e­cu­tion of these vi­tal pub­lic health func­tions. To­ward these goals we’re adopt­ing new pro­ce­dures that’ll re­duce the like­li­hood that they ac­crue bal­ances on their gov­ern­ment trav­el cred­it cards for cost of air­fare and ho­tel/lodg­ing,” he added.

First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Im­age: Scott Got­tlieb. SHUT­TER­STOCK

Daphne Koller, Getty

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

Bristol Myers Squibb is turning to one of the star upstarts in the machine learning world to go back to the drawing board and come up with the disease models needed to find drugs that can work against two of the toughest targets in the neuro world.

Daphne Koller’s well-funded insitro is getting $70 million in cash and near-term milestones to use their machine learning platform to create induced pluripotent stem cell-derived disease models for ALS and frontotemporal dementia.

Eli Lilly CEO David Ricks at the Rose Garden, May 26, 2020 (Evan Vucci/AP Images)

Eli Lil­ly lines up a block­buster deal for Covid-19 an­ti­body, right af­ter it failed a NI­AID tri­al

Two days after Eli Lilly conceded that its antibody bamlanivimab was a flop in hospitalized Covid-19 patients, the US government is preparing to make it a blockbuster.

The pharma giant reported early Wednesday that it struck a deal to supply the feds with 300,000 vials of the drug at a cost of $375 million — once it gets an EUA stamp from the FDA. And once that 2-month supply deal is done, the government has an option on another 650,000 doses on the same terms — which could potentially add another $812 million.

Eli Lilly CEO David Ricks (Evan Vucci/AP Images)

A P val­ue of 0.38? NE­JM re­sults raise new ques­tions for Eli Lil­ly's vaunt­ed Covid an­ti­body

Generally, a P value of 0.38 means your drug failed and by a fair margin. Depending on the company, the compound and the trial, it might mean the end of the program. It could trigger layoffs.

For Eli Lilly, though, it was part of the key endpoint on a trial that landed them a $1.2 billion deal with the US government to supply up to nearly 1 million Covid-19 antibodies.

So what does one make of that? Was the endpoint not so important, as Lilly maintains? Or did the US government promise a princely sum for a pedestrian drug?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

For AstraZeneca, the PACIFIC trial in Stage III non-small cell lung cancer remains one of the big triumphs for AstraZeneca’s oncology R&D group. It not only made their PD-L1 Imfinzi a franchise player with a solid advance in a large niche of the lung cancer market, the study — which continues to offer data on the long-range efficacy of their drug — also helped salve the vicious sting of the failure of the CTLA-4 combo in the MYSTIC study.

No­var­tis buys a new gene ther­a­py for vi­sion loss, and this is one pre­clin­i­cal ven­ture that did­n't come cheap

Cyrus Mozayeni got excited when he began to explore the academic work of Ehud Isacoff and John G. Flannery at UC Berkeley.

Together, they were engaged in finding a gene therapy approach to pan-genotypic vision restoration in patients with photoreceptor-based blindness, potentially restoring the vision of a broad group of patients. And they did it by using a vector to deliver the genetic sequence for light sensing proteins.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

Sanofi teams up with Mer­ck to pair Keytru­da with a next-gen IL-2 can­di­date from the Syn­thorx buy­out

Nearly a year after snapping up a next-gen immuno-oncology candidate in its $2.5 billion Synthorx buyout, Sanofi is joining forces with Merck to pair the drug with blockbuster Keytruda.

The pharmas are planning a Phase II trial of Sanofi’s non-alpha IL-2 candidate THOR-707 in combination or sequenced administration with Keytruda for various cancers. While the companies are keeping mum about the financial terms and targets, they said the trials will be Sanofi-sponsored.

CMO Merdad Parsey (Gilead)

Gilead hits the brakes on a tri­fec­ta of mid- and late-stage stud­ies for their trou­bled fil­go­tinib pro­gram. It's up to the FDA now

Gilead $GILD execs haven’t decided exactly what to do with filgotinib in the wake of the slapdown at the FDA on their rheumatoid arthritis application, but they’re taking a time out for a slate of studies until they can gain some clarity from the agency. And without encouraging guidance, this drug could clearly be axed from the pipeline.

In their Q3 report out Wednesday afternoon, the company says researchers have “paused” a Phase III study for psoriatic arthritis along with a pair of Phase II trials for ankylosing spondylitis and uveitis. Late-stage studies for ulcerative colitis and Crohn’s are continuing, but you can see for yourself how big a hole this leaves in the inflammatory disease pipeline, with obvious implications if the company abandons filgo altogether.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

Patrick Soon-Shiong at the JP Morgan Healthcare Conference, Jan. 13, 2020 (David Paul Morris/Bloomberg via Getty Images)

Af­ter falling be­hind the lead­ers, dissed by some ex­perts, biotech show­man Patrick Soon-Sh­iong fi­nal­ly gets his Covid-19 vac­cine ready for a tri­al. But can it live up to the hype?

In January, when dozens of scientists rushed to start making a vaccine for the then-novel coronavirus, they were joined by an unlikely compatriot: Patrick Soon-Shiong, the billionaire doctor most famous for making big, controversial promises on cancer research.

Soon-Shiong had spent the last 4 years on his “Cancer Moonshot,” but part of his project meant buying a small Seattle biotech that specialized in making common-cold vectors, called adenoviruses, to train the immune system. The billionaire had been using those vectors for oncology, but the company had also developed vaccine candidates for H1N1, Lassa fever and other viruses. When the outbreak began, he pivoted.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

Noubar Afeyan, Flagship founder and CEO (Victor Boyko/Getty Images)

UP­DAT­ED: Flag­ship launch­es Sen­da Bio­sciences with $88M in back­ing, look­ing to pi­o­neer the field of 'In­ter­sys­tems Bi­ol­o­gy'

Flagship Pioneering has a fresh company out this week, one that aims to lay the groundwork for a whole new discipline.

Senda Biosciences launched Wednesday with $88 million in Flagship cash. The goal? Gain insights into the molecular connections between people and coevolved nonhuman species like plants and bacteria, paving the way for “Intersystems Biology.”

Guillaume Pfefer has been tapped to run the show, a 25-year biotech veteran who comes from GSK after leading the development of the company’s shingles vaccine.